Restoration of Parenting Ability Through Treatment for Substance Use Disorders
|
|
- Darrell Harris
- 5 years ago
- Views:
Transcription
1 Restoration of Parenting Ability Through Treatment for Substance Use Disorders DEBRA M. BARNETT, MD Board Certified in General Psychiatry, Addiction Psychiatry, Geriatric Psychiatry, and Forensic Psychiatry
2 OBJECTIVES Participants will better understand what constitutes a substance use disorder. Participants will become more knowledgeable about the treatments for substance use disorders. Participants will be better able to engage persons in treatment with an appreciation for how treatment can produce successful recovery outcomes, including restoration of parenting abilities.
3 INTRODUCTION A common misperception is that persons with substance use disorders are difficult to treat and that they do not often successfully achieve recovery. Successful recovery is marked by a normalization of all aspects of a person s life, including their ability to parent. This workshop will use a PowerPoint format to examine engagement and treatment outcomes for substance use disorders. Case examples will be included.
4 WHAT IS A SUD? What defines a substance use disorder? 1. Medical/psychosocial 2. Screening and assessment 3. How a diagnosis is established 4. What is not a substance use disorder
5 Inebriety Among Women in This Country (Excerpts from JAMA October 29, 1892) This National folly of arresting and sending to jail these poor victims should cease. The practical point for our American physicians is to take up the subject of inebriety and study it as a purely medical topic, and not leave it to police courts and moralists to point out the evil and its remedies. The time is coming when the medical profession will teach the world the causes and remedies for this great and widespread evil of the century.
6 MEDICAL ASPECT- Biological basis: Acute effects of alcohol/drugs are to produce brain reward and reinforce, but the chronic neuroadaptation: Increases the threshold for reward Produces hedonic dysregulation Repeated use has caused conditioning to occur in related circuits Cues associated with use can activate the reward and withdrawal circuit This can evoke anticipation of the substance or feelings similar to withdrawal that can precipitate relapse in an abstinent person
7 Prefrontal Cortex Hippocampus Nucleus accumbens Amygdala Ventral tegmental area (VTA) Source: Messing RO. In: Harrison s Principles of Internal Medicine. 2001:
8 Similarities to Other Chronic Diseases 1-3 Characteristics Drug Dependence Diabetes, Asthma, and Hypertension Well studied Chronic disorder Predictable course Effective treatments Curable NO NO Heritable Requires continued care Requires adherence to treatment Requires ongoing monitoring Influenced by behavior Tends to worsen if untreated 1. McLellan AT et al. Addiction. 2005;100(4): ; 2. McLellan AT et al. JAMA. 2000;284(13): ; 3. McLellan AT. Addiction. 2002;97(3):
9 Patients Who Relapse (%) Relapse Rates Are Similar to Other Chronic Diseases 1, % 70% 50% 70% 40% 60% 30% 50% Drug Addiction Type 1 Diabetes Hypertension Asthma 1. McLellan AT et al. JAMA. 2000;284(13): ; 2. National Institute on Drug Abuse. Accessed June 30, 2011.
10 PSYCHOSOCIAL ASPECTS Impact on the individual, family, and community- embedded in the descriptions, definitions, and diagnostic criteria Historically, this was used to distinguish between habit and addiction
11 PSYCHOSOCIAL ASPECTS Pregnant women, 15 to 44yo, according to NSDUH average Illicit drug use Current 5.4%; compared to 11.4% for nonpregnant women By trimester 1 st 9%; 2 nd 4.8%; 3 rd 2.4% Alcohol use Current 9.4%; compared to 11.4% for nonpregnant women Binge drinking- 2.3%; Heavy drinking- 0.4% By trimester 1 st 19%; 2 nd 5%; 3 rd 4.4%
12 PSYCHOSOCIAL ASPECTS AFCARS 2016 Circumstances Associated With Child s Removal Neglect 61% (166,679) Drug Abuse (Parent) 34% (92,107) Caretaker Inability To Cope 14% (37,857) Physical Abuse 12% (33,671) Child Behavior Problem 11% (28,829) Housing 10% (27,871) Parent Incarceration 8% (20,939) Alcohol Abuse (Parent) 6% (15,143) Abandonment 5% (12,889) Sexual Abuse 4% (9,904) Drug Abuse (Child) 2% (6,273) Child Disability 2% (4,554) Relinquishment 1% (2,694) Parent Death 1% (2,212) Alcohol Abuse (Child) 0% (1,242)
13
14 DEFINITIONS: World Health Organization- Addiction: Repeated use of psychoactive substance(s), to the extent that the user is periodically or chronically intoxicated shows a compulsion to take the preferred substance(s), has great difficulty in voluntarily ceasing or modifying substance use, and exhibits determination to obtain psychoactive substances by almost any means. Typically, tolerance is prominent and a withdrawal syndrome frequently occurs when substance use is interrupted. The life of the addict may be dominated by substance use to the virtual exclusion of all other activities and responsibilities. DSM-5- Substance Use Disorder: Cluster of cognitive, behavioral, and physiological symptoms underlying change in brain circuits pathological pattern of behaviors
15 SCREENING INSTRUMENTS
16 THE DSM-5 DIAGNOSIS Substance Use Disorder Problematic pattern of use leading to clinically significant impairment or distress At least 2 (of 11 criteria) within a 12-month period First 4 reflect impaired control, 5-7 reflect social impairment, 8-9 are risky use, and are physiological dependence DSM-5 Merged Substance Abuse and Substance Dependence, eliminating use despite legal problems, and added craving/urges Specifiers In early remission- > 3 months but < 12 months In sustained remission- 12 months Severity Mild- 2-3 sx Moderate- 4-5 sx Severe- 6 sx
17 DSM-5 1. A/D is often taken in larger amounts or over a longer period than was intended. 2. There is a persistent desire or unsuccessful efforts to cut down or control use of A/D. 3. A great deal of time is spent in activities necessary to obtain A/D, use it, or recover from its effects. 4. Craving, or a strong desire or urge to use A/D. 5. Recurrent use of A/D resulting in a failure to fulfill major role obligations at work, school, or home. 6. Continued use of A/D despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of its use. 7. Important social, occupational, or recreational activities are given up or reduced because of use of A/D. 8. Recurrent use of A/D in situations in which it is physically hazardous. 9. Use of A/D is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by A/D. 10. Tolerance, as defined by either of the following: A need for markedly increased amounts of A/D to achieve intoxication or desired effect; A markedly diminished effect with continued use of the same amount of A/D. 11. Withdrawal, as manifested by either of the following: The characteristic withdrawal syndrome for A/D (refer to Criteria A and B of the criteria set for A/D withdrawal); A/D (or a closely related substance) is taken to relieve or avoid withdrawal symptoms.
18 WHAT IS NOT A SUBSTANCE USE DISORDER Tolerance and Withdrawal- This criterion is not considered to be met for those individuals taking opioids solely under appropriate (emphasis added) medical supervision. Pseudoaddiction? Single use misadventure- including violation of workplace drug policy Substance misuse which does not meet the criteria for a substance use disorder
19 BARRIERS TO ENGAGEMENT Felt they needed treatment and made an effort to get it, 351,000 Felt they needed treatment but did not try, 455,000 Did not feel they needed treatment, 16,900, National Survey on Drug Use and Health
20 BARRIERS TO ENGAGEMENT Might have negative effect on job Might cause neighbors or community to have negative opinion Did not find a program that offered the desired type of treatment Did not know where to go to get help No healthcare coverage and cannot afford Not ready to stop Percent Percent
21 ENGAGEMENT TECHNIQUES An empathetic non-judgmental interview style, reflected in the ease in which you ask relevant questions (think medical model) Motivational Interviewing Warm hand-off to a treatment provider Involuntary? Whether people initiate treatment because of external motivation or involuntarily, outcomes tend to be the same as if they initiated treatment voluntarily. Also incorporate a nonjudgmental approach; this is not being done as punishment
22 TREATMENT Intensity/Level of Care Self-help Outpatient and intensive outpatient Inpatient/residential, partial hospitalization, sober living Psychosocial Therapies Medication Assisted Treatment and Recovery
23 TREATMENT- ASAM LEVEL OF CARE GUIDELINES
24 TREATMENT- ASAM LEVEL OF CARE GUIDELINES
25 MAT and Psychosocial Intervention 1,2 Pharmacotherapy Can control symptoms by normalizing brain chemistry Psychosocial Intervention Essential to change behaviors and responses to environmental and social cues that so significantly impact relapse Both are necessary to normalize brain chemistry, change behavior, and reduce risk for relapse; neither alone may be sufficient 1. McLellan et al. Addiction. 1998;93(10): ; 2. McLellan et al. JAMA. 1993;269(15):
26 SUD Management- Pharmacotherapy AKA Medication Assisted Treatment and Recovery (MAT) Practice guidelines state that persons with certain SUDs should be offered medications as part of their treatment Alcohol Use Disorder Opioid Use Disorder
27 MAT Guidelines National Quality Forum s National Voluntary Consensus Standards for the Treatment of Substance Use Conditions: Evidence-Based Treatment Practices (p.vii) - recommends that pharmacotherapy should be made available to all adult patients diagnosed with opioid dependence, alcohol dependence, and nicotine dependence, as long as there are not medical contraindications. American Society for Addiction Medicine (ASAM) has an affirmative position on the use of medications for the treatment of alcohol use disorders in their ASAM Patient Placement Criteria: Supplement on Pharmacotherapies for Alcohol Use Disorders. National Institute on Drug Abuse (NIDA)- Medications are an important element of treatment for many patients, especially when combined with counseling and other behavioral therapies
28 MAT Guidelines- APA January 2018 APA recommends (1B) that naltrexone or acamprosate be offered to patients with moderate to severe alcohol use disorder who have a goal of reducing alcohol consumption or achieving abstinence, prefer pharmacotherapy or have not responded to nonpharmacological treatments alone, and have no contraindications to the use of these medications. APA suggests (2C) that disulfiram be offered to patients with moderate to severe alcohol use disorder who have a goal of achieving abstinence, prefer disulfiram or are intolerant to or have not responded to naltrexone and acamprosate, are capable of understanding the risks of alcohol consumption while taking disulfiram, and have no contraindications to the use of this medication.
29 Medication Assisted Treatment Alcohol Use Disorder Disulfiram (Antabuse) Acamprosate (Campral) Naltrexone oral (ReVia) Naltrexone IM monthly (Vivitrol) Probably also Gabapentin and Topirimate Each has data to support efficacy for various parameters such as duration of complete abstinence, prolonged time to relapse, fewer drinking days, fewer heavy drinking days, and craving
30 MAT- Alcohol Use Disorder Treatment provider Supplier Action/target Dosing Acamprosate Any prescribing healthcare provider Regular pharmacy Glutamate Orally, three times a day Naltrexone oral Any prescribing healthcare provider Regular pharmacy Opiate antagonism Orally, once daily Naltrexone IM monthly Any prescriber who also either provides the injection or refers Specialty pharmacy, ships cold overnight to prescriber Opiate antagonism IM, once a month Disulfiram Any prescribing healthcare provider Regular pharmacy Inhibits Aldehyde dehydrogenase Once daily
31 MAT- Alcohol Use Disorder Effect of Vivitrol on Complete Abstinence
32 MAT- Alcohol Use Dsorder Effects of Vivitrol on Number of Drinking Days
33 MAT- Alcohol Use Disorder Effects of Vivitrol on Heavy Drinking Days
34 Medication Assisted Treatment Opioid Use Disorder Methadone Naltrexone oral (ReVia) Naltrexone IM monthly (Vivitrol) Buprenorphine products (Suboxone, Zubsolv, Bunavail, Sublocade) Each has data to support efficacy for various parameters such as rates of opioid-free urine testing, treatment retention, and craving
35 MAT- Opioid Use Disorder Treatment provider Supplier Action/target Dosing Methadone Federally designated clinics Daily clinic visits for several months Opiate agonist Naltrexone oral Any prescribing healthcare provider Regular pharmacy Opiate antagonism Orally, once daily Naltrexone IM monthly Any prescriber who also either provides the injection or refers Specialty pharmacy, ships cold overnight to prescriber Opiate antagonism IM, once a month Buprenorphine +/- Naloxone Waivered prescriber; Most prescribing healthcare provider can qualify Regular pharmacy for oral doses; specialty pharmacy sends injectable to prescriber Partial opiate agonist Once daily for oral; once a month for injection
36 MAT- Opioid Use Disorder Benefits of treatment: Improve patient survival Increase retention in treatment Decrease illicit opiate use and other criminal activity among people with substance use disorders Increase patients ability to gain and maintain employment Improve birth outcomes among women who have substance use disorders and are pregnant Decreased potential for relapse decreases likelihood of contracting HIV or Hepatitis (SAMHSA, 2015)
37 MAT- Opioid Use Disorder
38 MAT- Opioid Use Disorder Duration Matters Primary Care Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence, A Randomized Clinical Trial; David A. Fiellin, MD, et. al.; JAMA Intern Med. 2014;174(12): week randomized, enrolled 113 patients with prescription opioid dependence from February, 2009, through February, 2013, in a single primary care site. BUP taper was initiated after 6 weeks of stabilization, lasted for 3 weeks, and included medications for opioid withdrawal, then patients were offered naltrexone treatment; the maintenance group received ongoing BUP therapy. Taper group: mean percentage of urine samples negative for opioids was lower; more days per week of illicit opioid use; fewer consecutive wks abstinent; less likely to complete the trial.
39 Prolonged Medication-Assisted Treatment Sustains Improvement After 6 Months 1 (buprenorphine-only; n=690) Heroin use decreased by 81% Codeine use decreased by 83% Benzodiazepine use decreased by 48% Cocaine use decreased by 74% After 18 Months 3 (buprenorphine/naloxone; n=176) After 12 Months 2 (buprenorphine-only; n=40) 32% improvement in occupational problems 90% improvement in drug-related problems 90% improvement in crime-related problems After 2-5 Years 4 (buprenorphine/naloxone; n=53) Less likely to report using any substance or heroin More likely to be employed Improved on several psychosocial parameters 91% of urine samples were opioid negative 96% of urine samples were cocaine negative 4 Studies of Various Treatment Lengths 1. Lavignasse P et al. Ann Med Interne (Paris). 2002:153(suppl 3):1S20-1S26; 2. Kakko J. Lancet. 2003;361(9358): ; 3. Parran TV et al. Drug Alcohol Depend. 2010:106(1):56-60; 4. Fiellin DA et al. Am J Addict. 2008;17(2):
40 MAT and Parenting Capacity Medication-Assisted Treatment Improves Child Permanency Outcomes for Opioid-Using Families in the Child Welfare System; Martin Hall, PhD, et.al.; Journal of Substance Abuse Treatment, 2016; 71; Of the 596 individuals with a history of opioid use in the START program, 55 (9.2%) received MAT. Receipt of MAT services did not differ by gender, age, county of residence, or drug use, though individuals who identified as White were more likely to participate in MAT. In a multiple logistic regression model, additional months of MAT increased the odds of parents retaining custody of their children.
41 HOW TO WORK WITH TREATMENT PROVIDERS Setting realistic expectations Understanding initial length of acute treatment, aftercare, continued engagement in recovery activities Understanding the slip/relapse and defining progress or failure Arrange for avenues of communication Acceptance of MAT
42 Case examples
Medication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More information2/21/2018. What are Opioids?
Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationOpioid Use Issues: All the Players
Opioid Use Issues: All the Players Objectives After review, the participant will be able to: 1) Identify criteria for opioid use disorders Andrew J. McLean, MD, MPH Medical Director, ND Department of Human
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationWasted AN INTRODUCTION TO SUBSTANCE ABUSE
Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Dr. Brian L. Bethel Child and Family Therapist Independent Trainer and Consultant LPCC-S, LCDC III, RPT-S www.brianlbethel.com INTERPLAY COUNSELING & CONSULTING
More informationMAT in the Corrections Setting
MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationSubstance Use Disorders
Substance Use Disorders Substance Use Disorder This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
More informationAppendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
More informationOpioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity
Opioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity Holly Hills, Ph.D. June 13, 2017 Department of Mental Health Law and Policy Overview: Persons who have not been in
More informationArwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry
The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationAddiction. Concept of Addiction R. Corey Waller MD, MS, FACEP, FASAM Director, Center for Integrative Medicine
Addiction Concept of Addiction R. Corey Waller MD, MS, FACEP, FASAM Director, Center for Integrative Medicine Twitter: @rcwallermd Objectives Understand the Concept of Addiction Survival FOOD WATER DOPAMINE
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationNeurobiology of Drug Abuse and Addiction PSYC 450
Neurobiology of Drug Abuse and Addiction PSYC 450 Healthy Control Drug Abuser Illicit drug use, lifetime and past year, in Canada 50 Canabis only Any drug Any of 5 drugs (without canabis) (CADUMS 2012)
More informationThe Importance of Psychological Treatment and Behavioral Support
The Importance of Psychological Treatment and Behavioral Support Michael W. Otto, PhD Department of Psychological and Brain Science Boston University Conflicts and Acknowledgements No industry funding
More informationDSM-5 AND ASAM CRITERIA. Presented by Jaime Goffin, LCSW
DSM-5 AND ASAM CRITERIA Presented by Jaime Goffin, LCSW MODULE 1: GOALS & OBJECTIVES What is your experience with using ASAM and DSM 5 criteria? What are your learning expectations for today? GOAL FOR
More informationTHE STATE OF MEDICINE IN ADDICTION RECOVERY
OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,
More informationTHE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.
THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.
More informationClosing the Loop in Treating Opioid Addiction:
Closing the Loop in Treating Opioid Addiction: Integrating MAT into Prison and Jail Health Systems May 9, 2018 Webinar Housekeeping All lines are muted This session will be recorded To ask a question:
More informationMark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC
Opioid Use Disorders and Their Treatment Mark Edlund, MD, PhD RTI International Photo courtesy of The Herb Museum, Vancouver, BC Acknowledgements Funded by NIDA R01 DA022560-01 NIDA R01 DA034627 NIDA R01
More informationNoel Schenk MD. Davis Behavioral Health
Noel Schenk MD Davis Behavioral Health Michael Botticelli Director of National Drug Control Policy What is Addiction? Addiction is defined as a chronic, relapsing brain disease that is characterized by
More informationSerious Mental Illness and Opioid Use Disorder
Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,
More informationMedication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford
Medication Assisted Treatment of an Opioid Use Disorder J. Craig Allen, MD. Medical Director, Rushford Learning objectives At the conclusion of this activity, participants will be able to: Understand
More informationInterdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings
Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings BRIAN GARVEY, MD, MPH REBECCA CANTONE, MD OREGON HEALTH & SCIENCE UNIVERSITY SCAPPOOSE RURAL HEALTH CENTER Disclosures
More informationTreatment Team Approaches in Substance Abuse Treatment
Treatment Team Approaches in Substance Abuse Treatment PLANT A SEED AND WATCH IT GROW 2 Substance use disorders span a wide variety of problems arising from substance use, and cover 11 different criteria:
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationNational Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says
National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says Last Updated February 2016 https://www.drugabuse.gov 1 Table of Contents Understanding Drug Abuse and Addiction:
More informationMedication for Addiction Treatment (MAT)
SBIRT Training Screening, Brief Intervention & Referral to Treatment Medication for Addiction Treatment (MAT) The Faith & Spirituality Integrated SBIRT Network Navigating the Training Welcome! These health
More informationShawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine
[Patient-focused, evidence-based addiction treatment] Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine BrightView Health All Rights Reserved www.brightviewhealth.com
More informationNORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Opioid Use Disorders Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 Opioid Use Disorders Importance of opioid use disorders Screening and
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationSubstance Abuse Level of Care Criteria
Substance Abuse Level of Care Criteria Table of Contents SUBSTANCE ABUSE OUTPATIENT: Adolescent... 3 SUBSTANCE ABUSE PREVENTION: Adult... 7 OPIOID MAINTENANCE THERAPY: Adult... 8 SUBSTANCE ABUSE INTERVENTION:
More informationDiscover the Hope: Opiate Treatment and Recovery
Discover the Hope: Opiate Treatment and Recovery The Continued Struggle to Find and Implement Best Practices Ted Parran JR. M.D. FACP Carter and Isabel Wang Professor of Medical Education CWRU School of
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationAcute General Medical and Surgical Admission:
Acute General Medical and Surgical Admission: Managing Substance Use Disorders in Patients Who are Severely Ill Scott Grantham, MD Executive Director, Behavioral Health Saint Francis Health System By the
More informationHot Topics in Addiction Medicine. Timothy Fong MD 44 th Annual Family Medicine Refresher March 2017
Hot Topics in Addiction Medicine Timothy Fong MD 44 th Annual Family Medicine Refresher March 2017 Financial Disclosures Speaker Bureau Indivior Research Support Constellation Health Onward Hot Topics
More informationCritiquing the Construction of Addiction: Dependence, Disorder and the DSM V
Critiquing the Construction of Addiction: Dependence, Disorder and the DSM V Helen Keane School of Sociology Australian National University Addiction A hybrid moral medical category defined by pathological
More informationWhat Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More information11/7/2016. Possession by evil spirits? Demon rum. Lack of moral fiber? War on drugs Just say no
Dean Drosnes, MD, FASAM Associate Medical Director Caron Treatment Centers ASAM Disclosure of Relevant Financial Relationships Date of Activity: Nov 3, 2016 Name Commercial Interests Relevant Financial
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationVivitrol Drug Court and Medication Assisted Treatment
Vivitrol Drug Court and Medication Assisted Treatment Amy Black, CNP and Judge Fred Moses Court program Self-starters Mission Statement To provide court-managed, medically assisted drug intervention treatment
More informationHealth Systems and Addiction: Provider Issues
Health Systems and Addiction: Provider Issues The Emerging Roles of Primary Care Patrick G. O Connor MD, MPH Dan and Amanda Adams Professor of General Medicine Chief, General Internal Medicine Yale University
More informationIdentification and Treatment of Opioid Use Disorders in Primary Care Settings
Identification and Treatment of Opioid Use Disorders in Primary Care Settings 17th Annual Primary Care Symposium February 24, 2018 Kelly S. Barth, DO Associate Professor, Psychiatry & Internal Medicine
More informationWHAT CAN I EXPECT?: DUAL SUBSTANCE USE AND MENTAL HEALTH TREATMENT FOR MILITARY POPULATIONS
WHAT CAN I EXPECT?: DUAL SUBSTANCE USE AND MENTAL HEALTH TREATMENT FOR MILITARY POPULATIONS René Lento, PhD Lauren Brenner, PhD September 25, 2018 DISCLOSURES None HOME BASE PROGRAM 3 LEARNING OBJECTIVES
More information6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder
Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of
More informationChild Welfare and MOMS: Building Partnerships to Improve Care
Child Welfare and MOMS: Building Partnerships to Improve Care Goals Develop collaborative partnerships between MOMS pilot sites and child welfare agencies: Facilitate successful outcomes for clients Jointly
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationCouncil on Chemical Abuse Annual Conference November 2, The Science of Addiction: Rewiring the Brain
Council on Chemical Abuse Annual Conference November 2, 2017 The Science of Addiction: Rewiring the Brain David Reyher, MSW, CAADC Behavioral Health Program Director Alvernia University Defining Addiction
More informationRECOMMENDATIONS FOR HEALTH CARE PROVIDERS
Ending Addiction Changes Everything RECOMMENDATIONS FOR HEALTH CARE PROVIDERS CRITICAL ADDICTION PREVENTION, TREATMENT AND MANAGEMENT SERVICES TO INCLUDE IN ROUTINE HEALTH CARE PRACTICE JULY 2013 In the
More informationMedication Assisted Treatment of Substance Use Disorders
3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard
More informationMedication-Assisted Treatment (MAT) for Opioid Use Disorders
Medication-Assisted Treatment (MAT) for Opioid Use Disorders Sybil Marsh MA MD FASAM Department of Family Medicine and Community Health Case Western Reserve University/UHCMC Learning Objective 1 Following
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More information8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy
Medication Assisted Treatment for Substance Abuse in Primary Care Dan Vinson August 1, 2013 1 The Big change in addiction medicine? These diseases are rapidly becoming medical diseases. Done are the days
More informationSANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery
Page 1 of 9 SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery Departmental Polley and Procedure Section Sub-section Alcohol and Drug Program (ADP) Effective: 7/11/2018
More informationOpioid Use Disorder Treatment: Buprenorphine Treatment Basics
Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Daniel Warren, MD Eastern Oregon Coordinated Care Organization Provider Forum on Chronic Noncancer Pain Management Pendleton, OR February 24,
More informationALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH
ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV
More informationThe Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) دکتر راد گودرزی
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 1 Expanded to include Gambling Disorder Cannabis Withdrawal and Caffeine Withdrawal are new disorders Caffeine Withdrawal
More informationEffective Treatment: Doing the Right Thing, In the Right Way. Terrence D Walton, MSW, ICADC
Effective Treatment: Doing the Right Thing, In the Right Way Terrence D Walton, MSW, ICADC Monitor Manage Impact 1. Understand the Treatment Field, including Evidenced Based Practices 2. Understand Your
More informationPain, Suffering, Over-Prescribing and Addiction What Have We Done, What Can We Do?
Pain, Suffering, Over-Prescribing and Addiction What Have We Done, What Can We Do? January 12, 2016 Trip Gardner, MD Chief Psychiatric Officer PCHC Noah Nesin, MD VP for Medical Affairs PCHC How Did We
More informationManagement Options for Opioid Dependence:
Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice
More informationSTARTING SUBOXONE IN PRIMARY CARE
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences STARTING SUBOXONE IN PRIMARY CARE MARK DUNCAN MD UNIVERSITY OF WASHINGTON OBJECTIVES 1. Review evidence of how to
More informationTreatment of Opioid Use Disorder
Treatment of Opioid Use Disorder Casia Horseman, MD Assistant Professor Department of Psychiatry and Behavioral Health The Ohio State University Wexner Medical Center Objectives Discuss the historical
More informationTreatment of Opioid Use Disorder
Treatment of Opioid Use Disorder Casia Horseman, MD Assistant Professor Department of Psychiatry and Behavioral Health The Ohio State University Wexner Medical Center Objectives Discuss the historical
More informationWhat is addiction and what can businesses do about it?
What is addiction and what can businesses do about it? Michael M. Miller, MD, DFASAM, DLFAPA Director of Addition Program Development and Training Rogers Behavioral Health Business Health Care Group April
More informationNURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS
Provider Name: NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE Provider Signature: Date: BUPRENORPHINE/NALOXONE CLINIC VISITS Once stable, schedule clinic visits every 2 to 4 weeks, with refills that coincide
More informationHIV and alcohol use: why is risk reduction in alcohol use important in HIV care?
HIV and alcohol use: why is risk reduction in alcohol use important in HIV care? Susanne Astrab Fogger, DNP, PMHNP-BC, CARN-AP, FAANP sfogger@uab.edu Objectives for today s session Define alcohol use disorder
More informationAn Internist s Guide to Unhealthy Alcohol Use. Ryan Graddy, MD JHU SOM
An Internist s Guide to Unhealthy Alcohol Use Ryan Graddy, MD JHU SOM Disclosures None Learning Objectives Understand the terminology used to describe unhealthy alcohol use Identify means of screening
More informationOpioid Analgesics: Responsible Prescribing in the Midst of an Epidemic
Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic Lucas Buffaloe, MD Associate Professor of Clinical Family and Community Medicine University of Missouri Health Care Goals for today
More informationDisclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.
Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of
More informationMASS COMMUNICATIONS The traditional realm of mass communications includes television,
Appendix C: Perspectives on Defining Substance c Abuse F our broad arenas that encounter substance abuse-related issues include, mass communications, criminal justice, medicine, and public health. These
More informationQUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.
2017 State Targeted Response to the Opioid Crisis Grants QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D. H.R.6-21st Century Cures Act The 21st Century Cures Act is a United States law enacted
More informationManagement of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
More informationSUBSTANCE USE DISORDER IN ADOLESCENT POPULATION
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences SUBSTANCE USE DISORDER IN ADOLESCENT POPULATION ANNABELLE SIMPSON, MD UNIVERSITY OF WASHINGTON GENERAL DISCLOSURES
More informationOpioids and Opioid Addiction: Practical Management Approaches
Opioids and Opioid Addiction: Practical Management Approaches Yngvild Olsen, MD, MPH Medical Director Institutes for Behavior Resources Inc/REACH Health Services Conflict of Interest No financial or advisory
More informationADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
More informationPharmacotherapy for Substance Use Disorders
Pharmacotherapy for Substance Use Disorders Vanessa de la Cruz, MD Chief of Psychiatry Mental Health and Substance Abuse Services Santa Cruz County Health Services Agency 1400 Emeline Avenue Santa Cruz,
More informationOverview of Opioid Use Disorder
Overview of Opioid Use Disorder Doug Burgess, MD Medical Director of Outpatient Services, Truman Medical Centers Assistant Professor of Psychiatry, University of Missouri- Kansas City Objectives History
More informationCorporate Medical Policy
Corporate Medical Policy Buprenorphine Implant for Treatment of Opioid Dependence File Name: Origination: Last CAP Review: Next CAP Review: Last Review: buprenorphine_implant_for_treatment_of_opioid_dependence
More informationOverview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University
More informationOpioid Epidemic Update
Opioid Epidemic Update - 2018 Talal Khan MD Addiction Psychiatrist Pine Rest What are Opioids? Opiates are alkaloid compounds naturally found in the opium Poppy plant. Papaver somniferum The psychoactive
More informationUnderstanding Medication in Addiction Treatment for Drug Court Participants
Understanding Medication in Addiction Treatment for Drug Court Participants Introduction This pocket guide is for drug court participants who may be prescribed or considering medication as a part of addiction
More informationOpioid Treatment in North Carolina SEPTEMBER 13, 2016
Opioid Treatment in North Carolina SEPTEMBER 13, 2016 Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users Aged 12 or Older: 2007 Source Where Respondent Obtained
More informationThe Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016
The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine March 10, 2016 Objectives Review current state of opioid crisis in Maine Briefly review physiology of
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationEVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO
EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO Lena Matthias Gray, MSA, CTTS-M University of Michigan MHealthy Tobacco Consultation Service Overview of Tobacco Use The World Health Organization
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationPharmacotherapy for Addiction A Practical Guide
A Practical Guide Poll Everywhere Text: 22333 Message: ROBYNJORDAN620 Assistance Professor of Psychiatry UNC School of Medicine Sept 28, 2018 Disclosures None Poll Everywhere Text: 22333 Message: ROBYNJORDAN620
More informationKRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH
KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH IF THESE MOMS REALLY CARED ABOUT THEIR BABIES, THEY WOULD JUST QUIT Those who can quit, often do Addiction
More information4/5/2018 MEDICATION ASSISTED TREATMENT FOR OPIOID USE DISORDERS OBJECTIVES DEFINITION OF ADDICTION APRIL 11, 2018 RITU BHATNAGAR, M.D., M.P.H.
MEDICATION ASSISTED TREATMENT FOR OPIOID USE DISORDERS APRIL 11, 2018 RITU BHATNAGAR, M.D., M.P.H. MEDICAL DIRECTOR, UNITYPOINT HEALTH MERITER/ NEWSTART ADJUNCT PROFESSOR, UNIVERSITY OF WISCONSIN MADISON
More informationPsychosocial Treatments for Opioid Use Disorder Overview
Psychosocial Treatments for Opioid Use Disorder Overview Nalan Ward, MD Director Outpatient Addiction Services Department of Psychiatry Massachusetts General Hospital *Images used for educational purposes
More informationClinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: 03.01.12 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationAssociate Medical Director of Addiction Medicine, Summa Physicians Inc., Akron, OH Medical Director Esper Treatment Center, Erie, PA Chief Medical
Associate Medical Director of Addiction Medicine, Summa Physicians Inc., Akron, OH Medical Director Esper Treatment Center, Erie, PA Chief Medical Officer, Interval Brotherhood Home, Akron, OH Director
More information